# Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Source: https://onco.cc/trials/nct07354074/  
OnCo record `nct07354074` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, now recruiting.

## Summary

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP is a phase 2 interventional study registered as NCT07354074 by Novartis Pharmaceuticals, with 50 participants planned, started 2026-04-28 and due to reach its primary completion in 2033-02-23. Interventions recorded: Asciminib single agent.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07354074
- Phase: 2
- Setting: A Phase II, Multicenter, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Participants Newly Diagnosed or Previously Treated With Philadelphia Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) With or Without Known T315I Mutation
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07354074: https://clinicaltrials.gov/study/NCT07354074

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- drugs: [Asciminib](https://onco.cc/drugs/asciminib/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct07354074.json